

Special Issue

Integrative Proteomics in Multifactorial Diseases

Message from the Guest Editor

Mass spectrometry-based proteomics is a crucial technology for advancing our understanding of biology and diseases. Recent breakthroughs made in proteomic technologies have allowed researchers to explore uncharted research areas, including post-translational modifications, interactomes, circulating proteomes, and immunopeptidomes. In addition, the integrative analysis of proteomics data with other omics data such as genomics, transcriptomics, and metabolomics is rapidly becoming a novel strategy used to achieve the next level of discoveries in biomarkers, therapeutic targets, drug targets, and the development of sensors. This Special Issue will collect studies related to the recent development of proteomic methods and their applications to research related to multifactorial diseases such as cancers, neurodegenerative diseases, and metabolic diseases, focusing on how proteomics and integrative multi-omics characterize the pathophysiology of diseases and help us to discover biomarkers, therapeutic targets, and sensor platforms.

- mass spectrometry
- proteomics
- immunopeptidome
- post-translational modification
- multi-omics
- systems biology
- precision medicine

Guest Editor

Dr. Min-Sik Kim

Department of New Biology, Daegu Gyeongbuk Institute of Science and Technology, Daegu 42988, Republic of Korea

Deadline for manuscript submissions

closed (31 July 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/116138

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).